JP2017533721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533721A5 JP2017533721A5 JP2017525921A JP2017525921A JP2017533721A5 JP 2017533721 A5 JP2017533721 A5 JP 2017533721A5 JP 2017525921 A JP2017525921 A JP 2017525921A JP 2017525921 A JP2017525921 A JP 2017525921A JP 2017533721 A5 JP2017533721 A5 JP 2017533721A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antisense compound
- composition according
- modified
- element region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080223P | 2014-11-14 | 2014-11-14 | |
| US62/080,223 | 2014-11-14 | ||
| US201562139626P | 2015-03-27 | 2015-03-27 | |
| US62/139,626 | 2015-03-27 | ||
| US201562156139P | 2015-05-01 | 2015-05-01 | |
| US62/156,139 | 2015-05-01 | ||
| US201562156812P | 2015-05-04 | 2015-05-04 | |
| US62/156,812 | 2015-05-04 | ||
| US201562233183P | 2015-09-25 | 2015-09-25 | |
| US62/233,183 | 2015-09-25 | ||
| PCT/US2015/060938 WO2016077837A1 (en) | 2014-11-14 | 2015-11-16 | Compounds and methods for the modulation of proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017533721A JP2017533721A (ja) | 2017-11-16 |
| JP2017533721A5 true JP2017533721A5 (enExample) | 2018-12-27 |
Family
ID=55955201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525921A Pending JP2017533721A (ja) | 2014-11-14 | 2015-11-16 | タンパク質の調節のための化合物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10822369B2 (enExample) |
| EP (1) | EP3218483A4 (enExample) |
| JP (1) | JP2017533721A (enExample) |
| AU (1) | AU2015346042A1 (enExample) |
| CA (1) | CA2964979A1 (enExample) |
| WO (1) | WO2016077837A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3533873A1 (en) | 2011-09-14 | 2019-09-04 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| CA2873779A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating mecp2 expression |
| JP2015529469A (ja) | 2012-09-14 | 2015-10-08 | ラナ セラピューティクス インコーポレイテッド | 多量体オリゴヌクレオチド化合物 |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| AU2015327836B2 (en) | 2014-10-03 | 2021-07-01 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| WO2016130943A1 (en) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
| CA2976576A1 (en) * | 2015-02-13 | 2016-08-18 | Translate Bio Ma, Inc. | Compositions and methods for modulating rna |
| US10525076B2 (en) | 2015-02-20 | 2020-01-07 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting genes associated with cystic fibrosis |
| EP3359685A1 (en) | 2015-10-09 | 2018-08-15 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| WO2017087282A1 (en) | 2015-11-18 | 2017-05-26 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease |
| US10370667B2 (en) | 2015-11-18 | 2019-08-06 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| ES2882500T3 (es) | 2015-12-14 | 2021-12-02 | Cold Spring Harbor Laboratory | Oligómeros antisentido para el tratamiento del síndrome de Dravet |
| JP7219207B2 (ja) * | 2016-07-29 | 2023-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 腫瘍関連マクロファージを標的化する抗体及びその使用 |
| JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
| RS65031B1 (sr) | 2017-08-25 | 2024-02-29 | Stoke Therapeutics Inc | Antisens oligomeri za lečenje stanja i bolesti |
| EP3740500A4 (en) * | 2018-01-17 | 2022-01-19 | The Florey Institute of Neuroscience and Mental Health | COMPOSITIONS AND METHODS TO INCREASE EXPRESSION OF SCN2A |
| KR20200120675A (ko) | 2018-02-14 | 2020-10-21 | 딥 지노믹스 인코포레이티드 | 윌슨병을 위한 올리고뉴클레오티드 요법 |
| JP2021523227A (ja) | 2018-05-04 | 2021-09-02 | ストーク セラピューティクス，インク． | コレステリルエステル蓄積症の処置のための方法及び組成物 |
| EP3942049A4 (en) | 2019-03-20 | 2023-10-18 | President And Fellows Of Harvard College | ANTISENSE OLIGONUCLEOTIDE BASED PROGRANULIN AUGMENTATION THERAPY FOR NEURODEGENERATIVE DISEASES |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| TW202208628A (zh) | 2020-05-13 | 2022-03-01 | 瑞士商赫孚孟拉羅股份公司 | 靶向顆粒蛋白前體之寡核苷酸促效劑 |
| WO2022098840A1 (en) * | 2020-11-05 | 2022-05-12 | The Jackson Laboratory | Modified antisense oligonucleotides targeting splicing factors |
| GB202107553D0 (en) * | 2021-05-27 | 2021-07-14 | Univ Oxford Innovation Ltd | Method |
| CN113584038B (zh) * | 2021-09-09 | 2023-11-14 | 深圳雅济科技有限公司 | 一种治疗视网膜疾病的反义寡核苷酸组合及其应用 |
| EP4430187A2 (en) * | 2021-11-10 | 2024-09-18 | University of Rochester | Antisense oligonucleotides for modifying protein expression |
| CA3255304A1 (en) * | 2022-05-25 | 2023-11-30 | Univ Yale | METHODS FOR TREATMENT, ALLEVIATION AND/OR PREVENTION OF POLYCYSTIC RENAL DISEASE AND POLYCYSTIC HEPATIC DISEASE |
| EP4581143A1 (en) * | 2022-08-29 | 2025-07-09 | University of Rochester | Antisense oligonucleotide-based anti-fibrotic therapeutics |
| WO2025043278A1 (en) * | 2023-08-25 | 2025-03-06 | PYC Therapeutics Limited | Gene-mediated conditions |
| WO2025165891A1 (en) | 2024-01-29 | 2025-08-07 | Arnatar Therapeutics, Inc | Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1341092A (en) | 1991-01-25 | 1992-08-27 | United States Biochemical Corporation | Regulation of nucleic acid translation |
| US6824976B1 (en) | 1993-04-02 | 2004-11-30 | Rigel Pharmaceuticals, Inc. | Method for selective inactivation of viral replication |
| US20040110144A1 (en) * | 2002-12-09 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of EMAP-II expression |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| US7718625B2 (en) | 2005-01-27 | 2010-05-18 | University Of South Florida | Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof |
| CN104884622B (zh) | 2012-12-21 | 2018-11-13 | 新西兰植物和食品研究院有限公司 | 基因表达的调控 |
| WO2014172698A1 (en) | 2013-04-19 | 2014-10-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
| EP3033425A4 (en) | 2013-08-16 | 2017-07-26 | Rana Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin |
| US20160201063A1 (en) | 2013-08-16 | 2016-07-14 | Rana Therapeutics, Inc. | Epigenetic regulators of frataxin |
| CA2921459A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Oligonucleotides targeting euchromatin regions of genes |
| AU2014306416B2 (en) | 2013-08-16 | 2021-02-25 | Translate Bio Ma, Inc. | Compositions and methods for modulating RNA |
| CA2921457A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Heterochromatin forming non-coding rnas |
-
2015
- 2015-11-16 JP JP2017525921A patent/JP2017533721A/ja active Pending
- 2015-11-16 US US15/525,232 patent/US10822369B2/en active Active
- 2015-11-16 AU AU2015346042A patent/AU2015346042A1/en not_active Abandoned
- 2015-11-16 CA CA2964979A patent/CA2964979A1/en not_active Abandoned
- 2015-11-16 WO PCT/US2015/060938 patent/WO2016077837A1/en not_active Ceased
- 2015-11-16 EP EP15859580.1A patent/EP3218483A4/en active Pending
-
2020
- 2020-09-15 US US17/021,510 patent/US12030910B2/en active Active
-
2024
- 2024-05-20 US US18/668,732 patent/US20250109164A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533721A5 (enExample) | ||
| Grimson et al. | Early origins and evolution of microRNAs and Piwi-interacting RNAs in animals | |
| JP2012029693A5 (enExample) | ||
| Chung et al. | MicroRNA and nephropathy: emerging concepts | |
| ES2617877T3 (es) | Composiciones de ARN interferente asimétrico y uso de las mismas | |
| JP2013516489A5 (enExample) | ||
| Wei | Coupling activators for the oligonucleotide synthesis via phosphoramidite approach | |
| JP2018512110A5 (enExample) | ||
| Adkar-Purushothama et al. | Potato spindle tuber viroid infection triggers degradation of chloride channel protein CLC-b-like and Ribosomal protein S3a-like mRNAs in tomato plants | |
| JP2009219504A5 (enExample) | ||
| JP2016533765A5 (enExample) | ||
| JP2017093448A5 (enExample) | ||
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| FI4220360T3 (fi) | Oligonukleotideja paternaalisen ube3a:n ilmentämiseksi | |
| JP2012510297A5 (enExample) | ||
| JP2017505623A5 (enExample) | ||
| RU2019124314A (ru) | Сопряженные антисмысловые соединения и их применение | |
| EP4372091A3 (en) | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | |
| JP2009532392A5 (enExample) | ||
| JP2017524348A5 (enExample) | ||
| HRP20191471T1 (hr) | Molekule nukleinske kiseline modificirane saharidom | |
| US20050123952A1 (en) | Methods of rapid detection and identification of bioagents using microRNA | |
| JP2015511821A5 (enExample) | ||
| JP2016528887A5 (enExample) | ||
| PE20191047A1 (es) | Compuestos y metodos para reducir de la expresion de atxn3 |